Home
November 2008 December 2008 January 2009
Su Mo Tu We Th Fr Sa
Week 49 1 2 3 4 5 6
Week 50 7 8 9 10 11 12 13
Week 51 14 15 16 17 18 19 20
Week 52 21 22 23 24 25 26 27
Week 1 28 29 30 31

Laser Technique Shows Promise as Treatment for Uterine Myomas Show Comments PDF Print E-mail
Monday, 09 September 2002
NEW YORK (Reuters Health) - Interstitial laser photocoagulation (ILP), a technique that has been successfully used for fibroadenomas of the breast, also appears to be an effective therapy for uterine myomas, according to a recent report.

NEW YORK (Reuters Health) - Interstitial laser photocoagulation (ILP), a technique that has been successfully used for fibroadenomas of the breast, also appears to be an effective therapy for uterine myomas, according to a recent report.

The technique involves the insertion of optical fibers into lesions located deep inside solid organs. Low-power laser energy is then applied, which destroys the target lesion without damaging overlying normal tissues.

In the current study, Dr. Stephen G. Bown, from Royal Free and University College in London, and colleagues used ILP on 30 myoma lesions in 24 symptomatic patients who refused surgical resection. The optical fibers were placed in the lesions under laparoscopic guidance.

The researchers' findings are published in the August issue of the American Journal of Obstetrics and Gynecology.

The procedure was well tolerated and none of the patients required hospital admission, the authors note. Twenty-three lesions were found to have shrunk on follow-up ultrasound or MRI. Lesions greater than 6 cm in diameter tended to be resistant to treatment. An improvement in clinical symptoms was noted in 13 patients.

The findings indicate that "ILP is a safe, well-tolerated procedure that can shrink uterine myomas," the researchers conclude. Some of its main advantages are that "it is repeatable and that it does not prevent subsequent conventional surgical procedures," they add.

Based on these encouraging preliminary findings, larger studies are warranted to further evaluate the safety and efficacy of ILP for uterine myomas, the investigators urge.

Am J Obstet Gynecol 2002;187:382-384.


Copyright © 2003 Reuters Limited. All rights reserved. Republication or redistribution of Reuters Limited content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters Limited. Reuters Limited shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Reader Comments

Please log-in or register in order to submit comments.

Powered by AkoComment!

 
User Rating: / 0
PoorBest


 
< Prev   Next >